A new mode of probiotic therapy: Specific targeting

Einat Amit-Romach, Zehava Uni, Michael Friedman, Itzhak Aizenberg, Zippi Berkovich, Ram Reifen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Luminal bacteria are the most probable inducers of inflammatory bowel disease (IBD). The intestinal microbiota can be modified by probiotics, which reduce symptoms in IBD, via stimulation of the intestinal immune system. We aimed to evaluate the effects of oral and rectal administration of probiotics, on the morphology, gene expression, and microbial ecology of the colon, in a rat trinitrobenzenesulfonic acid (TNBS) model. Colitis was induced with simultaneous rectal or oral administration of probiotics. Both routes of introduction significantly increased the relative amounts of Lactobacillus spp. Rectal introduction almost eradicated damage to the tissue, while enteral introduction only improved it. Only rectal probiotics significantly decreased myeloperoxidase activity, and altered mucin and Toll-like receptor mRNA expression in the colon, to values close to control. We suggest that targeted introduction should be considered not only for probiotics but also for nutrients such as amino acids and vitamins into the colon and intestine.

Original languageAmerican English
Pages (from-to)386-392
Number of pages7
JournalJournal of Functional Foods
StatePublished - 1 Jun 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ltd.


  • Colitis
  • Probiotics
  • Targeting
  • Therapy


Dive into the research topics of 'A new mode of probiotic therapy: Specific targeting'. Together they form a unique fingerprint.

Cite this